Cart
sales@molnova.com
Neuropeptide FF
CAS No. 99566-27-5
Neuropeptide FF( NPFF )
Catalog No. M29773 CAS No. 99566-27-5
Endogenous antiopioid peptide and agonist at NPFF1 and NPFF2 receptors (Ki values are 2.82 and 0.21 nM respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameNeuropeptide FF
-
NoteResearch use only, not for human use.
-
Brief DescriptionEndogenous antiopioid peptide and agonist at NPFF1 and NPFF2 receptors (Ki values are 2.82 and 0.21 nM respectively).
-
DescriptionEndogenous antiopioid peptide and agonist at NPFF1 and NPFF2 receptors (Ki values are 2.82 and 0.21 nM respectively).
-
In Vitro——
-
In Vivo——
-
SynonymsNPFF
-
PathwayGPCR/G Protein
-
TargetNeuropeptide Y Receptor
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number99566-27-5
-
Formula Weight1081.27
-
Molecular FormulaC54H76N14O10
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (92.48 mM)
-
SMILES——
-
Chemical NameSequence:{Phe}{Leu}{Phe}{Gln}{Pro}{Gln}{Arg}{Phe}-NH2
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Mankus JV, et al. Nonpeptide ligands of neuropeptide FF: current status and structural insights. Future Med Chem. 2012 Jun;4(9):1085-92.
molnova catalog
related products
-
Spexin
Potent galanin receptor 2/3 (GAL2/GAL3) agonist (EC50 values are 45.7 and 112.2 nM, respectively). Exhibits no significant activity at galanin receptor 1. Endogenous satiety-inducing peptide; inhibits long chain fatty acid uptake by adipocytes and decreases food consumption in diet-induced obese mice and rats. Attenuates LH secretion in goldfish. Exhibits anxiolytic effects in vivo.
-
Neuropeptide FF
Endogenous antiopioid peptide and agonist at NPFF1 and NPFF2 receptors (Ki values are 2.82 and 0.21 nM respectively).
-
Velneperit
Velneperit is potent and selective neuropeptide Y (NPY) Y5 receptor under evaluating for treatment of obesity.
